A case of methamphetamine use disorder treated with the antibiotic drug minocycline

General Hospital Psychiatry

Volumn 32, Issue 5, 2010, Pages 559.e1-559.e3

  Tanibuchi, Yuko ^a,b,c   Shimagami, Minoru ^b   Fukami, Goro ^a   Sekine, Yoshimoto ^c   Iyo, Masaomi ^a   Hashimoto, Kenji ^c  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Fukaya Mental Clinic   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; METHAMPHETAMINE; MINOCYCLINE; NITRAZEPAM; OLANZAPINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TRAZODONE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; AGGRESSION; AKATHISIA; ANOREXIA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EVENING DOSAGE; FEMALE; HALLUCINATION; HUMAN; INSOMNIA; JAPANESE; MORNING DOSAGE; PSYCHOSIS; SUBSTANCE ABUSE; SUICIDAL IDEATION; TREATMENT RESPONSE;

EID: 77956880411     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2009.12.005     Document Type: Article

References (13)

1. Ujike H., Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci 2004, 1025:279-287.
2. Hashimoto K. New research on methamphetamine abuse. New Research on Methamphetamine Abuse 2007, 1-51. NovaScience Publishers, Inc., New York. G.H. Toolaney (Ed.).
3. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001, 158:1206-1214.
4. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M., et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 2006, 63:90-100.
5. Schuckit M.A., Saunders J.B. The empirical basis of substance use disorders diagnosis: research recommendations for the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V). Addiction 2006, 101(Suppl 1):170-173.
6. Volkow N.D., Fowler J.S., Wang G.J., Baler R., Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(Suppl 1):3-8. Epub 2008.
7. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., et al. Methamphetamine causes microglial activation in the brain of human abusers. J Neurosci 2008, 28:5756-5761.
8. Hashimoto K. Microglial activation and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1758-1759.
9. Zhang L., Kitaichi K., Fujimoto Y., Nakayama H., Shimizu E., Iyo M., et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuro-Psychopharmacol Biol Psychiatry 2006, 30:1381-1393.
10. Hashimoto K., Tsukada H., Nishiyama S., Fukumoto D., Kakiuchi T., Iyo M. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a PET study in conscious monkeys. Biol Psychiatry 2007, 61:577-581.
11. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008, 31:287-292.
12. Levkovitz Y., Mendlovich S., Issaki S., Braw Y., Levkovitz-Verbin H., Gal G., et al. A double blind randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2009, Nov. 3. [Epub ahead of print].
13. Hashimoto K. Minocycline as a therapeutic drug for methamphetamine use disorders. Nihon Shinkei Seishin Yakurigaku Zasshi 2008, 28:19-22.